Capillary Electrophoresis Evaluated for Hemoglobinopathy Testing
|
By LabMedica International staff writers Posted on 25 May 2015 |

Image: The Minicap Flex Piercing capillary zone electrophoresis system (Photo courtesy of Sebia).
The detection of structural hemoglobin (Hb) variants and thalassemia has become increasingly important in clinical laboratories of all countries with a large influx of immigrants over the past 10 years.
Guidelines for hemoglobinopathy screening not only recommend the use of quantitative techniques for thalassemia detection, they also stress the use of a confirmatory method when an Hb variant is detected. In an ideal setting, both techniques can be met by a combination of high-performance liquid chromatography (HPLC) and capillary zone electrophoresis (CZE).
Scientists at the University Hospital Leuven (Belgium) and their colleagues evaluated a suitable stand-alone method for hemoglobinopathy screening of approximately 50 clinical samples a week. The studied the analytical performance of a CZE and set up a comparison with two well-established HPLC methods.
Capillary zone electrophoresis was performed using the Minicap Flex Piercing CZE system (Sebia; Norcross, GA, USA). The instrument is equipped to resuspend, lyse, separate, and analyze whole blood samples for variants collected in ethylenediaminetetraacetic acid (EDTA) tubes. The lysed red cells are electrophoresed in alkaline buffer (pH 9.4) allowing separation to be directed by pH and endosmosis. Detection of eluting hemoglobin species is accomplished using the change in absorbance at 415 nm. CZE does not require daily calibration, but normal HbA and HbA2 migration controls are analyzed daily through each capillary before additional quality control (QC), or patient samples are run to ensure proper charge and function of both capillaries. The two well-established HPLC methods were the Bio-Rad Variant Classic and the Bio-Rad D-10 instruments (Bio-Rad Laboratories; Hercules, CA, USA).
The analytical performance was acceptable for the determination of HbA, HbA2, HbS, and HbF, with an imprecision equal to or less than 2.0%. Method comparison showed a linear correlation for HbA2, HbF, and HbS measurements. Clinical concordance was acceptable when comparing CZE and HPLC. Hb variant presumptive identification was evaluated by analyzing seven samples with confirmed heterogeneous or homogeneous presence of Hb variants: two HbC, one HbD, one HbE and HbA2'. One sample was compound heterogeneous for HbS and HbC. On the Minicap Flex Piercing, a minimal overlap between HbC and HbA2 was found.
The authors concluded that as HPLC methods have the advantage of a great precision in detection of a large number of variants, it has the disadvantage of a complex elution pattern that may be difficult to interpret for many routine chemistry laboratories. The Minicap Flex Piercing showed similar analytical performance compared to previous published work using CZE. As for HPLC, CZE gives only a provisional identification of variant hemoglobins, and confirmation by an alternative method based on a different principle is needed. The study was published in the June 2015 issue of the International Journal of Laboratory Hematology.
Related Links:
University Hospital Leuven
Sebia
Bio-Rad Laboratories
Guidelines for hemoglobinopathy screening not only recommend the use of quantitative techniques for thalassemia detection, they also stress the use of a confirmatory method when an Hb variant is detected. In an ideal setting, both techniques can be met by a combination of high-performance liquid chromatography (HPLC) and capillary zone electrophoresis (CZE).
Scientists at the University Hospital Leuven (Belgium) and their colleagues evaluated a suitable stand-alone method for hemoglobinopathy screening of approximately 50 clinical samples a week. The studied the analytical performance of a CZE and set up a comparison with two well-established HPLC methods.
Capillary zone electrophoresis was performed using the Minicap Flex Piercing CZE system (Sebia; Norcross, GA, USA). The instrument is equipped to resuspend, lyse, separate, and analyze whole blood samples for variants collected in ethylenediaminetetraacetic acid (EDTA) tubes. The lysed red cells are electrophoresed in alkaline buffer (pH 9.4) allowing separation to be directed by pH and endosmosis. Detection of eluting hemoglobin species is accomplished using the change in absorbance at 415 nm. CZE does not require daily calibration, but normal HbA and HbA2 migration controls are analyzed daily through each capillary before additional quality control (QC), or patient samples are run to ensure proper charge and function of both capillaries. The two well-established HPLC methods were the Bio-Rad Variant Classic and the Bio-Rad D-10 instruments (Bio-Rad Laboratories; Hercules, CA, USA).
The analytical performance was acceptable for the determination of HbA, HbA2, HbS, and HbF, with an imprecision equal to or less than 2.0%. Method comparison showed a linear correlation for HbA2, HbF, and HbS measurements. Clinical concordance was acceptable when comparing CZE and HPLC. Hb variant presumptive identification was evaluated by analyzing seven samples with confirmed heterogeneous or homogeneous presence of Hb variants: two HbC, one HbD, one HbE and HbA2'. One sample was compound heterogeneous for HbS and HbC. On the Minicap Flex Piercing, a minimal overlap between HbC and HbA2 was found.
The authors concluded that as HPLC methods have the advantage of a great precision in detection of a large number of variants, it has the disadvantage of a complex elution pattern that may be difficult to interpret for many routine chemistry laboratories. The Minicap Flex Piercing showed similar analytical performance compared to previous published work using CZE. As for HPLC, CZE gives only a provisional identification of variant hemoglobins, and confirmation by an alternative method based on a different principle is needed. The study was published in the June 2015 issue of the International Journal of Laboratory Hematology.
Related Links:
University Hospital Leuven
Sebia
Bio-Rad Laboratories
Latest Clinical Chem. News
- New Blood Test Index Offers Earlier Detection of Liver Scarring
- Electronic Nose Smells Early Signs of Ovarian Cancer in Blood
- Simple Blood Test Offers New Path to Alzheimer’s Assessment in Primary Care
- Existing Hospital Analyzers Can Identify Fake Liquid Medical Products
- Rapid Blood Testing Method Aids Safer Decision-Making in Drug-Related Emergencies
- New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
- Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
- Study Compares Analytical Performance of Quantitative Hepatitis B Surface Antigen Assays
- Blood Test Could Predict and Identify Early Relapses in Myeloma Patients
- Compact Raman Imaging System Detects Subtle Tumor Signals
- Noninvasive Blood-Glucose Monitoring to Replace Finger Pricks for Diabetics
- POC Breath Diagnostic System to Detect Pneumonia-Causing Pathogens
- Online Tool Detects Drug Exposure Directly from Patient Samples
- Chemical Imaging Probe Could Track and Treat Prostate Cancer
- Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
- VOCs Show Promise for Early Multi-Cancer Detection
Channels
Clinical Chemistry
view channelNew Blood Test Index Offers Earlier Detection of Liver Scarring
Metabolic fatty liver disease is highly prevalent and often silent, yet it can progress to fibrosis, cirrhosis, and liver failure. Current first-line blood test scores frequently return indeterminate results,... Read more
Electronic Nose Smells Early Signs of Ovarian Cancer in Blood
Ovarian cancer is often diagnosed at a late stage because its symptoms are vague and resemble those of more common conditions. Unlike breast cancer, there is currently no reliable screening method, and... Read moreMolecular Diagnostics
view channel
Ultra-Sensitive DNA Test Identifies Relapse Risk in Aggressive Leukemia
Acute myeloid leukemia (AML) is a rare but aggressive blood cancer in which relapse after allogeneic stem cell transplant remains a major clinical challenge, particularly for patients with NPM1-mutated disease.... Read more
Blood Test Could Help Detect Gallbladder Cancer Earlier
Gallbladder cancer is one of the deadliest gastrointestinal cancers because it is often diagnosed at an advanced stage when treatment options are limited. Early symptoms are minimal, and current screening... Read moreImmunology
view channel
New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read moreBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Hidden Gut Viruses Linked to Colorectal Cancer Risk
Colorectal cancer (CRC) remains a leading cause of cancer mortality in many Western countries, and existing risk-stratification approaches leave substantial room for improvement. Although age, diet, and... Read more
Three-Test Panel Launched for Detection of Liver Fluke Infections
Parasitic liver fluke infections remain endemic in parts of Asia, where transmission commonly occurs through consumption of raw freshwater fish or aquatic plants. Chronic infection is a well-established... Read morePathology
view channel
Molecular Imaging to Reduce Need for Melanoma Biopsies
Melanoma is the deadliest form of skin cancer and accounts for the vast majority of skin cancer-related deaths. Because early melanomas can closely resemble benign moles, clinicians often rely on visual... Read more
Urine Specimen Collection System Improves Diagnostic Accuracy and Efficiency
Urine testing is a critical, non-invasive diagnostic tool used to detect conditions such as pregnancy, urinary tract infections, metabolic disorders, cancer, and kidney disease. However, contaminated or... Read moreTechnology
view channel
Blood Test “Clocks” Predict Start of Alzheimer’s Symptoms
More than 7 million Americans live with Alzheimer’s disease, and related health and long-term care costs are projected to reach nearly USD 400 billion in 2025. The disease has no cure, and symptoms often... Read more
AI-Powered Biomarker Predicts Liver Cancer Risk
Liver cancer, or hepatocellular carcinoma, causes more than 800,000 deaths worldwide each year and often goes undetected until late stages. Even after treatment, recurrence rates reach 70% to 80%, contributing... Read more
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreIndustry
view channel
Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss
Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more







